Disc Medicine Announces Bitopertin Met All Endpoints in APOLLO Phase 3 Trial for EPP
Disc Medicine announced bitopertin met all primary and secondary endpoints in the APOLLO Phase 3 trial for erythropoietic protoporphyria, signaling a potential breakthrough treatment. The company plans to resubmit the NDA by the end of 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed